Regulatory Milestones and Legal Challenges Shape Johnson & Johnson's Path

Johnson & Johnson files for first-ever wAIHA therapy, partners with Blackstone on cancer drug, and faces a lawsuit from Bayer over marketing claims for Erleada.

Johnson & Johnson has taken a significant step toward addressing an unmet medical need by submitting a supplemental application to the U.S. Food and Drug Administration (FDA) for a rare blood disorder therapy. This positive development coincides with the healthcare giant facing a new lawsuit from a competitor concerning marketing claims for an established cancer drug.

Strategic Partnership and Shareholder Returns

Beyond its internal pipeline, Johnson & Johnson is leveraging external expertise to advance its oncology portfolio. On February 23, 2026, the company entered into a funding agreement with Blackstone Life Sciences. This collaboration will support clinical trials from Phase 1 through Phase 3 for Bleximenib, an oral Menin inhibitor being developed for acute myeloid leukemia. Blackstone Life Sciences manages assets worth $15 billion.

From a shareholder perspective, the company's stock achieved a new 52-week high of $247.25 on February 25, 2026. Furthermore, a quarterly dividend of $1.30 per share is scheduled for distribution to shareholders on March 10, 2026.

Seeking Approval for First-Ever wAIHA Treatment

The FDA submission, filed on February 24, 2026, seeks to expand the use of the drug IMAAVY (nipocalimab-aahu). The application aims to secure its approval as the first sanctioned therapy for warm autoimmune hemolytic anemia (wAIHA). This rare condition, affecting approximately 1 in 8,000 people in the United States, is associated with a 20 to 30 percent increase in mortality risk. Current treatment options are limited, often forcing physicians to prescribe corticosteroids or immunosuppressants that are not officially approved for this specific use.

Data supporting the submission comes from the Phase 2/3 ENERGY study. Results indicated that patients treated with IMAAVY achieved sustained hemoglobin levels of at least 10 g/dL, representing an increase of 2 g/dL or more over a period of 28 days or longer. The drug works by blocking the neonatal Fc receptor, thereby reducing circulating IgG autoantibodies. IMAAVY previously received FDA approval for myasthenia gravis in April 2025.

Legal Dispute Over Cancer Drug Marketing Claims

Simultaneously, Johnson & Johnson is confronting legal allegations. Bayer filed a lawsuit against the corporation and its subsidiary, Janssen Biotech, in a federal court in Manhattan on February 23, 2026. The complaint centers on accusations of misleading promotion for the prostate cancer medication, Erleada.

Bayer alleges that Johnson & Johnson utilized flawed retrospective real-world data to claim that Erleada reduces mortality risk by 51 percent compared to Bayer's own therapy, Nubeqa. The lawsuit points to purported methodological issues, including a patient cohort for Erleada that was five times larger than the group studied for Nubeqa. It also states that many patients in the Nubeqa group received the drug outside of its approved indications. In its defense, Johnson & Johnson has stood by its analysis, citing adherence to rigorous real-world evidence standards. Nubeqa generated over $1.8 billion in revenue in 2025.